Literature DB >> 21073618

Clinical study on lymph node metastatic recurrence in patients with N0 esophageal squamous cell cancer.

Zhi-Gang Sun1, Zhou Wang.   

Abstract

Esophageal squamous cell cancer (ESCC) is one of the most common malignancies treated by thoracic surgeons. It is aggressive and generally associated with a poor prognosis. One of the most important prognostic factors is the presence of the lymph node metastasis (LNM). The purpose of the present study was to investigate the risk factor with lymph node metastatic recurrence in patients with N0 esophageal squamous cancer after Ivor Lewis esophagectomy based on the detection of mucin1 (MUC1) mRNA. The subjects were 82 patients with pN0 ESCC who underwent Ivor Lewis esophagectomy with two-field lymph node dissection from January 2001 to January 2005. All lymph nodes (501 stations) obtained from these patients were reevaluated by reverse transcriptase-polymerase chain reaction (RT-PCR) to detect MUC1mRNA. The diagnosis of lymph node micrometastasis (LNMM) was based on the detection of MUC1 mRNA. The Kaplan-Meier method was used to calculate the survival rate and lymph nodal metastatic rate. Log-rank test was performed to compare the recurrence rate, and Cox regression multivariate analysis was performed to determine independent prognostic factors. The overall 3-year survival rates of 82 patients were 78.0%, and the first recurrence exhibiting lymph nodal metastasis was recognized in 37 patients (45.1%) in the first 3 years after operation. Lymph node metastatic rate in patients in the first 3 years after operation was significantly associated with the T status (P < 0.05). MUC1 mRNA was identified in at least one lymph node station from 23 (28.1%) patients. Also, lymph node metastatic rate of the patients with LNMM was significantly higher than that of the patients without LNMM (P < 0.01).The results of multivariate analysis confirmed that LNMM and T status in patients with N0 ESCC were independent risk factors for 3-year lymph node metastatic recurrence after Ivor Lewis esophagectomy. Adjunctive therapy might be beneficial in controlling the locoregional recurrence and elevated healing rates for certain patients.
© 2010 Copyright the Authors. Journal compilation © 2010, Wiley Periodicals, Inc. and the International Society for Diseases of the Esophagus.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21073618     DOI: 10.1111/j.1442-2050.2010.01125.x

Source DB:  PubMed          Journal:  Dis Esophagus        ISSN: 1120-8694            Impact factor:   3.429


  6 in total

1.  Genome-wide association study identifies common variants in SLC39A6 associated with length of survival in esophageal squamous-cell carcinoma.

Authors:  Chen Wu; Dong Li; Weihua Jia; Zhibin Hu; Yifeng Zhou; Dianke Yu; Tong Tong; Mingrong Wang; Dongmei Lin; Yan Qiao; Yuling Zhou; Jiang Chang; Kan Zhai; Menghan Wang; Lixuan Wei; Wen Tan; Hongbing Shen; Yixin Zeng; Dongxin Lin
Journal:  Nat Genet       Date:  2013-05-05       Impact factor: 38.330

2.  Specific MUC1 splice variants are correlated with tumor progression in esophageal cancer.

Authors:  Kolsoum Rezaie Kahkhaie; Omeed Moaven; Mohammad Reza Abbaszadegan; Mehdi Montazer; Mehran Gholamin
Journal:  World J Surg       Date:  2014-08       Impact factor: 3.352

Review 3.  Lymph Node Metastases in Esophageal Carcinoma: An Endoscopist's View.

Authors:  Jin Woong Cho; Suck Chei Choi; Jae Young Jang; Sung Kwan Shin; Kee Don Choi; Jun Haeng Lee; Sang Gyun Kim; Jae Kyu Sung; Seong Woo Jeon; Il Ju Choi; Gwang Ha Kim; Sam Ryong Jee; Wan Sik Lee; Hwoon-Yong Jung
Journal:  Clin Endosc       Date:  2014-11-30

4.  Clinical and prognostic significance of MUC1 expression in patients with esophageal squamous cell carcinoma after radical resection.

Authors:  Zhi-Gang Sun; Li Yu; Wei Gao; Zhou Wang; Liang-Ming Zhu
Journal:  Saudi J Gastroenterol       Date:  2018 May-Jun       Impact factor: 2.485

5.  Ferroptosis-Related lncRNA Signature Correlates with the Prognosis, Tumor Microenvironment, and Therapeutic Sensitivity of Esophageal Squamous Cell Carcinoma.

Authors:  Jiahao Zhu; Yutian Zhao; Gang Wu; Xiaojun Zhang; Qingqing Chen; Bo Yang; Xinwei Guo; Shengjun Ji; Ke Gu
Journal:  Oxid Med Cell Longev       Date:  2022-07-16       Impact factor: 7.310

6.  Postoperative Radiotherapy in Pathological T2-3N0M0 Thoracic Esophageal Squamous Cell Carcinoma: Interim Report of a Prospective, Phase III, Randomized Controlled Study.

Authors:  Wei Deng; Jinsong Yang; Wenjie Ni; Chen Li; Xiao Chang; Weiming Han; Zongmei Zhou; Dongfu Chen; Qinfu Feng; Jun Liang; Jima Lv; Xiaozhen Wang; Xin Wang; Lei Deng; Wenqing Wang; Nan Bi; Tao Zhang; Yexiong Li; Shugeng Gao; Qi Xue; Yousheng Mao; Kelin Sun; Xiangyang Liu; Dekang Fang; Dali Wang; Jian Li; Jun Zhao; Kang Shao; Zhishan Li; Xinjie Chen; Lei Han; Lifang Wang; Jie He; Zefen Xiao
Journal:  Oncologist       Date:  2020-02-21
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.